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From this linked cohort, all infants born between April 1, 1999 and March 31, 2007
were selected and characteristics of those receiving Palivizumab were described.
Among infants with an indication to receive Palivizumab (i.e. born35 weeks, CHD
or BPD), recipients were compared with non-recipients and determinants of receiv-
ing Palivizumab were examined using logistic regression analyses. RESULTS:
Among the 3321 infants with an indication to receive Palivizumab, only 15% were
recipients. The majority was born32 weeks of gestation and mean age at first use
was 3.1 months. The strongest predictor of receiving Palivizumab was being born
32 weeks (OR 49.1; 95%CI 31.5-76.4). However, among the infants born32 weeks,
still 50% did not receive Palivuzmab. Subanalyses among this group showed that
the likelihood of receiving Palivizumab was higher for infants born in later years,
having respiratory distress syndrome or being hospitalized in the RSV season.
CONCLUSIONS: In the Netherlands, Palivizumab is mostly prescribed to infants
born32 weeks, which is according to Dutch guidelines. Use has increased over the
years. However, not all children addressed in the label indication are receiving
Palivizumab.
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OBJECTIVES: Information on the implementation of national (NVL) and interna-
tional guidelines (GINA and GOLD) for asthma and COPD in German clinical prac-
tice is limited. METHODS: Research on inhaled corticosteroid/long-acting 2-ago-
nists (ICS/LABA) in asthma and COPD in Germany was conducted by a modified
Delphi Process with a panel of physicians (six GPs and four pulmonologists) to
produce 25 consensus statements. RESULTS: Three consensus statements provide
insight into current controversies on ICS/LABA use in German clinical practice.
Consensus on the statement “Early initiation onto ICS/LABA therapy can improve
asthma control and help reduce the rate of exacerbations for patients with persis-
tent asthma who are not sufficiently controlled”, suggests that this is current clin-
ical practice in Germany, consistent with GINA, rather than with the NVL recom-
mendation of doubling the ICS dose. The panel agreed that stepping down LABA in
established ICS/LABA therapy, would lead to loss of control and/or worsening of
symptoms in around 50% of patients. It was agreed that by early initiation of ICS/
LABA in uncontrolled asthma 70–80% of health care resource utilisation could be
avoided. Another statement: “A typical patient that should be initiated on ICS/
LABA has moderate to severe COPD, suffers from symptoms and experiences ex-
acerbations” suggests that clinical practice among German physicians anticipated
the 2011 GOLD guideline, in which initiation of a fixed ICS/LABA combination is
based on combined assessment of COPD severity including exacerbation history
and the presence of symptoms. The panel estimated that timely initiation of ICS/
LABA therapy in COPD patients could prevent 10–40% of unscheduled visits (hos-
pitalisations, emergency room and physician visits). CONCLUSIONS: The results of
this research suggest that early initiation of ICS/LABA therapy could substantially
reduce unscheduled treatment costs in asthma patients, and that timely introduc-
tion of LABA/ICS therapy for COPD patients could substantially reduce both un-
scheduled treatment and hospitalisation costs.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is a major public
health problem. It is often under-diagnosed and undertreated. Prevalence of COPD
is strongly correlated with smoking habits but it affects non-smokers (including ex-
and passive smokers) also. Early and effective treatment can reduce health care
resource use by decreasing the severity and number of exacerbations. Indacaterol
is an “ultra”-long-acting 2-agonist indicated for long-term maintenance broncho-
dilator treatment of airflow obstruction in patients with COPD. METHODS: We
estimated the prevalence of COPD, and the incidence of exacerbations in a single
hospital district with 200,000 inhabitants (Etelä-Pohjanmaa) in one year. Popula-
tion-based data and smoking habits were utilized. Published indacaterol data were
used to estimate the incidence and severity of exacerbations w/wo medication.
Health care resource use was included from both primary and secondary health
care. RESULTS:The estimated number of COPD patients in the hospital district was
13,700 (prevalence 6.85%, out of which 49% were currently non-smokers and 42% in
working age). The patient population potentially benefiting from treatment (GOLD
stages I-IV), was estimated to be 12,000 (87.6% of all COPD-patients). Within one
year, without medication the number of expected exacerbations was 8,634, 3% of
them were severe (needing hospitalization). Applying data from published inda-
caterol trial, 31% of exacerbations could be avoided by medical treatment. This can
lead to a reduction of inpatient days by 800, and outpatient visits by 2,555 among
this patient population in this hospital district. CONCLUSIONS: Based on the
model, in this hospital district, COPD affects almost 7% of the population. In addi-
tion to elderly heavy smokers, health care workers should be aware of the large
working age non-smoking population with possibility of having COPD. Early detec-
tion and effective treatment of COPD may decrease the number of exacerbations
and consequently reduce the use of health care resources.
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OBJECTIVES: To assess continuity of care and to examine any association between
continuity of care and health outcomes (hospitalization, emergency department
visits, deaths and medical costs in Korea. METHODS: This was a retrospective
cohort study using the Korea National Health Insurance Claim Database. Patients,
40 years of age, who were diagnosed with COPD in 2007 (n49,635) were moni-
tored for four years, until 2010. RESULTS: As continuity of care increased, the risks
of hospitalization, emergency department visits, and deaths decreased, as did
medical costs. Also, variables that had significant affects on continuity level for
COPD patients were gender, age, experience of hospitalization, frequency of am-
bulatory visits, number of institution visited, the type of the main clinics attended,
and Charlson’s score. The correlation analysis regarding continuity levels and odds
ratios of health outcomes for COPD patients produced the following results. In
comparison between the first quartile group and the fourth quartile group of COC,
the fourth quartile group had higher rate of hospitalization by 1.61 (95% CI: 1.51-
1.72), a higher emergency department usage by 1.53 (95% CI: 1.41-1.67), and an
increased death rate by 1.26 (95% CI: 1.02-1.56). The odds of fourth quartile belong-
ing to the high costing group were also higher than first quartile (OR1.54, 95% CI:
1.44-1.64). The associations of COC with health outcomes and costs were stronger
when analysing patients visiting a primary institution, as their main attending
medical institution. CONCLUSIONS: As a result, it is proven that improving the
continuity level reduces the risk of hospitalization, ER visits, deaths and medical
costs in COPD patients. Therefore, policy makers needs to develop and actively
move forward the program to improve the continuity level of care in patients with
COPD, especially for the patients using the primary health care service.
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OBJECTIVES: To assess continuity of care and to examine any association between
continuity of care and health outcomes (hospitalization, emergency department
visits), also effects on medical costs. METHODS: This was retrospective cohort
study using the Korea National Health Insurance Claim Database. Patients, 40
years of age, who were first diagnosed with COPD in 2008 (n34,249) were moni-
tored for the following 2 years at specific index dates. RESULTS: The mean of the
COC was 0.91970.1859 retrospectively. As the continuity of care increased, the
risks of hospitalization and emergency department visits decreased, along with
medical costs. Also, variables that have significant affects on continuity level for
COPD patients were gender, age, experience of hospitalization, frequency of am-
bulatory visits, number of institution visited, type of the main attended clinic, the
first attending medical institution, and Charlson’s score. The correlation analysis
on the continuity levels, and hazard ratios of health outcomes showed the follow-
ing results. Comparing the continuity group by COC, the non-continuity group had
higher rate of hospitalization by 1.70 (95% CI: 1.54-1.87) and an increased emer-
gency department usage by 1.70 (95% CI: 1.46-1.99). The risk of non-continuity
group belonging to the high costing group were also higher than the continuity
group (OR1.54, 95% CI: 1.44-1.64). The associations of COC, with health outcomes
and costs, were stronger when analysing patients visiting primary institution as
opposed to attending main medical institutions. CONCLUSIONS: As a result, it is
proven that to improve continuity level, one needs to reduce the risk of deterio-
rated condition and medical costs in COPD patients. Therefore, the policy makers
need to develop and try actively to alter the program to improve the continuity
level of care in patients with COPD, especially for the patients using primary health
care service.
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OBJECTIVES: To document real world management and resource use for patients
with CF. METHODS: Retrospective, medical chart review in eight CF centres in UK.
A stratified random sample of charts was selected from the cohort of patients 6
years of age with a diagnosis of CF caused by genotypes G551D or DF508 homozy-
gous. The study period covered the most recent two years of complete data. Patient
and clinical characteristics, health care resource and drug usage were extracted.
Categorical variables were described as number and proportion of patients and
continuous variables were summarised using descriptive statistics. RESULTS:Data
for 200 patients (50% female, mean age 19.5) were reviewed, with N63 (32%) hav-
ing G551D genotype. Severity distribution measured using FEV1% was: 40%27,
40% and 70%69 and 70%96 patients respectively. Twenty different health
care professional types provided care. Nearly all patients (N199) had a clinic visit
(mean15.2 per patient, SD9.1, median13), and 23% (N45) having an emer-
gency visit (mean2.4 per patient, SD2.2, median2). For drug usage, IV antibi-
otics (73.5%, N147), nebulised therapy (87.0%, N174), and mucolytic treatment
(74.5%, N149) were frequently used. Pancreatic enzyme treatment was used by
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96.5% (N193), with N180 indicating continuous use. N141 patients (71%) had a
hospitalization with average 3.5 hospitalizations per patient (median2); an aver-
age patient spent 48 days in hospital during the study period. On average, for those
with a procedure, 1.8 (SD1.4) surgical (N55) or 7.9 (SD5.8) diagnostic (N200)
procedures were recorded. No differences were observed between G551D and
DF508 genotypes in terms of severity of disease as gauged by health care use.
CONCLUSIONS: This study, linking both clinical and resources use information
indicates that high frequency and intensity of health care resource use contributes
substantially to the overall burden of CF in UK. G551D and 	F508 genotypes appear
to have similar patterns of resource utilization.
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OBJECTIVES: Long-acting 2-agonists (LABAs), such as formoterol fumarate (for-
moterol) and salmeterol xinafoate (salmeterol), play key roles in the management
of asthma and chronic obstructive pulmonary disease. This analysis evaluated new
prescriptions of inhaled LABAs for respiratory disease in five European countries
during 2011. METHODS: Data on new prescriptions for LABAs, as either a single
drug or a fixed-dose combination (FDC), were collected from anonymized patient
records obtained via primary care physician practice management software (Cege-
dim Strategic Data, Surrey, UK) from January until December 2011 in five European
countries (France, Germany, Italy, Spain and UK). New prescriptions were defined
as those issued to patients who had not received a product from the selected
market in the previous 12 months; patients who were prescribed a LABA or FDC
therapy as a replacement for an existing therapy; and patients for whom a LABA
was added to their continued, original therapy. RESULTS:Overall, there were more
than 7.44 million new prescriptions for LABAs during 2011, either as monotherapy
(1.38. million; 18.5%) or as FDCs (6.07 million; 81.5%). Formoterol accounted for
55.2% (4.11 million) of all new LABA prescriptions, compared with 39.7% (2.96 mil-
lion) for salmeterol and 5.1% (0.38 million) for indacaterol. Formoterol comprised
53.7% of LABA monotherapy prescriptions compared with 18.8% for salmeterol and
27.5% for indacaterol. For FDCs, formoterol accounted for 55.5% of new prescrip-
tions (budesonide/formoterol, 32.8%; beclometasone/formoterol, 22.7%) compared
with 44.5% for salmeterol/fluticasone.CONCLUSIONS: Formoterol is the most com-
monly prescribed inhaled LABA for patients with respiratory disease, who are
newly prescribed LABA therapy, as either a single drug or combination therapy, in
the five largest European countries. These data may reflect, at least in part, physi-
cian preference for formoterol-containing regimens based on their well-estab-
lished efficacy profile.
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OBJECTIVES: To evaluate the association between persistent use of statins and the
risk of incident psoriasis among primary prevention patients in community
settings.METHODS:A cohort of 205,820 adults aged21 years, with no indication
of psoriasis or psoriatic arthritis, who began statin therapy between 1998 and 2009
in Maccabi Healthcare Services, a large health maintenance organization in Israel,
was followed retrospectively for psoriasis. Persistence with statins was measured
by the proportion of days covered (PDC) with dispensed prescriptions of statins
during follow-up period. Psoriasis was counted if diagnosed by a dermatologist or
at release from hospitalization. Sex-stratified Cox proportional hazards regression
was used for analysis of risk of psoriasis by PDC level, adjusting for baseline demo-
graphic and clinical characteristics, initial statin efficacy and baseline use of
beta-blockers. RESULTS: A total of 5160 cases of incident psoriasis were identified
during the follow-up period (1.3 million person-years) with incidence density rate
of 4.40/1,000PY (95% CI: 4.29-4.52). Multivariate analysis revealed a U-shaped asso-
ciation between persistence with statins and onset of psoriasis. In comparison with
non-persistent users (20% PDC), in women, HRs declined with increasing PDC to
0.74 (95% CI: 0.65-0.85) in the 40-60% PDC group and then increased up to 0.88
(0.79-0.98) in the most persistent group (80% PDC). In men, HRs declined to 0.84
(0.74-0.95) and then increased up to 1.00 (0.90-1.11) in respective PDC groups. Lim-
iting analyses to patients with more than 5 years of follow-up yielded similar
results. Beginning treatment with high efficacy statins was associated with an
11-18% reduced risk of psoriasis. CONCLUSIONS: Our large community-based study
indicates a U-shaped association between statins use and the risk of psoriasis.
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This research was carried out during a review of the manufacturer’s submission
(MS) to the NICE Single Technology Appraisal programme for the humanised re-
combinant monoclonal antibody fragment, ranibizumab. OBJECTIVES: Although
novel agents for the treatment of MO secondary to branch RVO (BRVO) or central
RVO (CRVO) are available, there is limited evidence on their clinical effectiveness
compared with existing treatments, and with each other. This research compared
the clinical effectiveness of ranibizumab versus standard care, dexamethasone
intravitreal implant (dexamethasone), and bevacizumab in patients with MO sec-
ondary to CRVO or to BRVO. METHODS: Randomised controlled trials (RCTs) for
inclusion were identified using the MS for ranibizumab. RCTs were assessed for
comparability based on treatment regimen, patient population, and disease sever-
ity. Adjusted indirect comparisons and a linear network analysis (3 RCTs) were
performed. Summary statistics used were relative risk of achieving an improve-
ment of 15 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters and
mean difference (MD) in ETDRS letters from baseline. RESULTS: Indirect compari-
sons of ranibizumab versus dexamethasone indicated a relative risk of achieving
an improvement of 15 letters or more of 0.53 (95% CI: 0.26 to 1.07) in MO secondary
to CRVO at 6 months and 0.56 (95% CI: 0.33 to 0.96) in MO secondary to BRVO at 3
months. In MO secondary to BRVO, a linear network analysis indicated an MD of
–2.9 ETDRS letters (95% Credible interval [CrI]: –10.0 to4.3) between bevacizumab
and ranibizumab, and an MD of –8.0 ETDRS letters (95% CrI: –17.0 to1.2) between
grid laser photocoagulation (standard care) and ranibizumab. The direction of ef-
fect favoured ranibizumab in all analyses. CONCLUSIONS: The available evidence
for analysis is insufficient to draw any firm conclusions on the comparative effects
of active treatments for MO secondary to RVO. Additional RCTs are required.
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OBJECTIVES: To investigate the effect of Epidermal Growth Factor (EGF) plus silver
sulfadiazine (SSD) cream for treatment of burn wound. METHODS: The 34 patients
who have partial thickness burn wounds and admitted at Burn Unit, Siriraj hospital
during December 2011 to April 2012 were randomly divided into 2 groups receiving
the topical treatment either 6% EGF plus 1% SSD cream group (study group) or 1%
silver zinc sulfadiazine cream (control group). The study end point was the time of
completely wound closure. Area of wound measurement and wound dressing was
done every day. Percentage of epithelialization, pain and itching score, pain and
itch medication used and chemistry laboratory results were evaluated every week
until completely wound closure by epithelialization. RESULTS: The demographic
data of both groups was similar with regards to sex, age, weight, social history, vital
sign and wound characteristics. From this study, we found that the study group
had significantly shorter healing time than of the control group. The study group
also had higher percentage of epithelialization at every time points (p0.05). How-
ever, there was no significant difference in percentage of wound contraction be-
tween both groups (p0.05). Pain score and doses of pain-relieved medication used
(paracetamol and morphine) in study group was significantly lower than in the
control group. There was no difference in itching evaluation and itch-relieved med-
ication used and blood chemistry parameters (p0.05). The cost of treatment was
similar in both groups even length of stay in study group was less compared to
control group. CONCLUSIONS: Topical EGF plus silver sulfadiazine enhances
wound healing in partial thickness burn wounds by reduced time of wound closure
without any serious side effects. EGF application may be a new option for burn
wound care in the future.
PSS4
ACNE AND LIFESTYLE: RESULTS OF A SURVEY ON A REPRESENTATIVE SAMPLE
OF THE FRENCH POPULATION
Wolkenstein P1, Misery L2, Amici JM3, Maghia R4, Cazeau C5, Voisard JJ5, Taieb C6
1Creteil Hospital, Creteil, France, 2Brest Hospital, Brest, France, 3Hôpital Saint André, Bordeaux,
France, 4Dermatology, Brives, France, 5PFD, Lavaur, France, 6CREES PFSA, Boulogne, France
OBJECTIVES: Acne is influenced by lifestyle1. Smoking, weight and diet have all
been identified as playing a role. Polls are a quick way to explore a population. The
aim of our study was to investigate factors associated with acne in a representative
sample of the French population reporting acne. METHODS: A total of 10,084 sub-
jects constituting a representative sample of French people aged 15 to 69years were
interviewed by the CSA Health Institute according to the quota method (sex-age-
socio-professional category and location). The questionnaire explored the BMI,
lifestyle, addictions (smoking-alcohol-cannabis), diet, sexuality, stress and physi-
cal activity. The subjects reporting mild, moderate or severe acne were also
compared. RESULTS: A total of 2073 subjects were identified. 843 boys (477cases-
and-366controls) and 1,230 girls (857cases-and-373controls). Among these cases,
46 reported severe-acne, 417 moderate-acne and 871 mild-acne. Overall, the cases
included significantly fewer smokers, more virgin subjects, a higher reported-
stress rate, and a lower BMI. Consumption of alcohol, cannabis and soda, the fre-
quency of fast-food consumption, and the level of physical activity did not differ
between the cases and controls. The severity of acne was not associated with BMI,
physical activity, oral contraception (for girls), sexuality, alcohol consumption or
the feeling of being stressed. However, there was a significantly higher number of
smoking subjects in the severe group compared to the subjects in the moderate and
mild groups (33.3%-18.71%-and-18.37%-respectively-were-smokers). The same
correlation was observed for cannabis, fast-food , soda , daily chocolate/confec-
tionery and dairy product consumption. CONCLUSIONS: There is a link between
lifestyle, acne and its severity. Factors such as smoking and a high-fat or high-
sugar diet seem to be associated with more severe acne. Our results are obtained
from a self-reported population. Nevertheless, and the analysis of our survey sup-
plement the results obtained from a case-control study. We confirm that there is a
link between lifestyle and acne, in particular food.
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